OGEN Oragenics Inc.

0.94
+0.01  (+1%)
Previous Close 0.93
Open 0.93
Price To Book 3.92
Market Cap 27667147
Shares 29,433,135
Volume 859,683
Short Ratio 0.36
Av. Daily Volume 7,279,602

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214845
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181177846
  3. 8-K - Current report 181125495
  4. 8-K - Current report 181111275
  5. 8-K - Current report 181097487

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due late-2019.
AG013
Oral mucositis (OM)

Latest News

  1. Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review
  2. Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma
  3. Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives
  4. Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event
  5. Recent Analysis Shows Liberty Global, New Oriental Education & Technology Group, Platinum Group Metals, Asure Software, Oragenics, and MGE Energy Market Influences — Renewed Outlook, Key Drivers of Growth
  6. OGEN: Phase 2 Trial of AG013 Adds Clinical Sites in Europe…
  7. Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
  8. Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update
  9. Oragenics: 3Q Earnings Snapshot
  10. Positive Global Healthcare Outlook Could Push 3 Stocks Higher
  11. Today’s Research Reports on Stocks to Watch: Fresenius Medical Care and Oragenics
  12. Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
  13. Today's Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals
  14. This Week’s Biotech and Cannabis Stocks to Watch
  15. Should You Worry About The Oragenics Inc’s (NYSEMKT:OGEN) Shareholder Register?
  16. These Stocks Are on The Brink of Breakouts
  17. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  18. Biotech Market is Rolling and These Companies Need to Be on Your Radar
  19. Oragenics, Inc. to Present at Upcoming Conferences in October
  20. Today’s Research Reports on Stocks to Watch: Oragenics and Pfizer

SEC Filings

  1. 8-K - Current report 181214845
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181177846
  3. 8-K - Current report 181125495
  4. 8-K - Current report 181111275
  5. 8-K - Current report 181097487
  6. 8-K - Current report 181086197
  7. 8-K - Current report 181019858
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181012998
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012657
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 18965124